Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoniazid + pyridoxine is a fixed-dose combination of two small molecule drugs used primarily in the treatment and prevention of tuberculosis (TB). Isoniazid acts as an antimycobacterial agent by inhibiting the synthesis of mycolic acids, essential components of the mycobacterial cell wall, leading to bacterial death. Pyridoxine (vitamin B6) is included to prevent or reduce peripheral neuropathy, a common side effect associated with isoniazid therapy. This combination improves patient adherence and safety by reducing pill burden and minimizing neurological adverse effects[4][9][8]. It may be used alone or as part of multidrug regimens for TB management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoniazid + pyridoxine.